{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fmetex14-nsclc-faq-part-2-jC5IxTfi","width":444,"version":"1.0","type":"rich","title":"MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/68af8073-29ce-405c-8042-2f3259ba4a7e/asco-metex14-podcasticon.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/d01edb99-3dd1-40a7-b7ae-8a4f58d636c3\" height=\"200\" width=\"100%\" title=\"MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to international lung cancer experts Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, as they answer audience questions from a live CCO Webinar on <i>MET</i>ex14 mutation–positive NSCLC, from guidance on biomarker testing to sequencing of immunotherapy with MET inhibitors in these patients."}